Optibiotix Health Share Discussion Threads

[parob] 25/1/2017 09:08

Well that dip was soon bought into and reversed.....now back to the rising trend!

[scotty1] 25/1/2017 08:58

diamond yuo relly oght to raed wat yuo hve witten and ave a spelceck bfore postin :)

[rafboy] 25/1/2017 08:50

Diamond, do you mean patents?

[diamond fibre] 25/1/2017 08:44

More paitences coming.

[someuwin] 25/1/2017 08:05

Over 80p by end of the week imo.

[parob] 25/1/2017 07:55

From the proactive article yesterday:"With the microbiome fast becoming a rapidly growing area of interest, OptiBiotix is well positioned to be one of the leaders in this field," claims finnCap's Alex Pye.

[someuwin] 25/1/2017 07:52

From the link in SOH email yesterday...

Cleveland Clinic Unveils Top 10 Medical Innovations Most Likley To Be Game Changers
A panel of top doctors and researchers presents the advancements with the power to transform healthcare in 2017
October 26, 2016

Topping the 11th annual list is the harnessing of the microbiome, the gut bacteria swarming in all of us. Recent discoveries have revealed the power of microbes to prevent, diagnose and treat disease. The healthcare industry will soon be pouring resources into addressing the potential for new therapies, diagnostics, probiotics and other products.

1. Using the Microbiome to Prevent, Diagnose and Treat Disease

When it comes to life-saving potential and market opportunities, the gut is a gold mine. Trillions of bacteria making up communities in our body – the microbiome – are unlocking mysteries at a rapid pace as the market scrambles to address the possibilities.

The crux of the discovery, made within the last 10 years, is that our microbes have a mind of their own. The chemicals they emit interfere with the way food is digested, medicine is deployed, and even how a disease progresses.

Biotech companies once focused on the genomic market are pivoting to the potential of the microbiome to develop new diagnostics, new therapies, and “probioticR21; products to prevent dangerous microbe imbalances.

With the National Microbiome Initiative accelerating research and development, experts believe 2017 is the year the microbiome cements itself as the healthcare industry’s most promising and lucrative frontier.

[judijudi] 25/1/2017 07:44

Looking at the end of day trading we need some buyers this morning to stop the weak taking control again
Have some dry gunpowder if it does happen to go to far down

[aspex] 25/1/2017 01:23

The sales near the end of day do not suggest the quick sell off shown. It shows how a few small moves can widen prices. It will be interesting if there is a reversal in the morning.Note to john henry. You are close to where I live, in the fourth most expensive city in the world. It does not feel like I live in a one million pound house and I will not be taking the money, just yet!

[elrico] 25/1/2017 00:57

Great stuff - someuwin & Parob,

JH - don't you put that ring on...they will hunt you down!

[spike_1] 24/1/2017 20:40

someuwin,
indeed brilliant. Means much more to me than the dry RNS this morning.!

Best wishes - Mike

[whl2] 24/1/2017 20:31

JH

It's currently 7 degrees centigrade in Wigan - you bas*ard !!

[john henry] 24/1/2017 20:29

Some excellent news recently, catching up where and when I can as currently touring New Zealand, Southern Hemisphere for 6 months. Currently in the Bay of Islands. GLA

[diamond fibre] 24/1/2017 19:55

Brilliant.

[parob] 24/1/2017 19:53

Cheers someuwin.

Not only is SOH speaking at the Asia Microbiome conference, Optibiotix is an event sponsor! See page 4 of the agenda.



WHAT IS SIGNIFICANT is the reference to reducing cholesterol by 27%! This if the first time I have seen this figure mentioned! See below (from page 13 of the agenda - Stephen is speaking on Weds 1st March at 15.45pm)

COMPANY SHOWCASE: STEPHEN OHARA
Founder and CEO, OptiBiotix Health plc Targeted microbiome modulation: next generation pre-, pro-, and OptiBiotics This work reports on studies in human gut models which have shown the ability of OptiBiotix’s microbiome modulators to increase the growth rate and biological effect of specific microbial species in the human microbiome. This has been demonstrated in multiple species, including OptiBiotix’s cholesterol reducing probiotic strain (LP-LDL®). LP-LDL® has been shown to significantly reduce both total and LDL cholesterol in independent human studies.

Crude cell extracts of LP-LDL® were used to synthesize GOS (LPGOS) from lactose, which was purified, and added alone or in combination with the parent LP-LDL® strain to pH-controlled, batch cultures in the presence of cholesterol. The results show that LPGOS significantly and selectively increased Lactobacillus populations and reduced cholesterol by more than 20%. Cholesterol reduction was further enhanced by combining LPGOS with its parent LP-LD® strain, lowering cholesterol by 27%. This was a threefold improvement in cholesterol reduction than that achieved by LP-LDL® alone. The biological effect correlated with Lactobacillus concentrations indicating a synergistic effect that was not observed when LP-LDL® was used in combination with a control GOS, which had no an impact on cholesterol reduction.

These studies suggest potential for:

The development of species or genera specific prebiotics which can selectively enhance the growth and health benefits of existing probiotic products. This new product concept, called an OptiBiotic®, has the potential to enhance probiotic health benefits and provide product differentiation in the probiotic market, a market forecast to be worth more than $46.5bn by 2020 (Markets and Markets).

Designer ingredients which can modify an individual’s current microbiome to improve health. As LPGOS is heat resistant and stable during processing this creates the opportunity to incorporate low cost, safe, cholesterol lowering ingredients, in a wide range of food products.

[judijudi] 24/1/2017 19:43

Cheers someu :)

[whl2] 24/1/2017 19:37

Thanks for sharing, someuwin

[someuwin] 24/1/2017 19:33

I asked SoH for a bit more info following today's RNS.

Just got this excellent response...

"Hi

I can’t give out any market sensitive information but I can help investors understand the potential implications of our research. All of this has already been reported but I will attempt to pull it together in one place to answer your question. The key points in the RNS are i and ii.

Lets start with the premise that we believe, as do many health commentators, that the microbiome will have a major effect on the prevention, management, and treatment of humans disease. There is growing support for this with leading US researchers and clinicians at a Medical Innovation Summit at the end of 2016 identifying the microbiome as the leading medical innovation they believe has the power to transform healthcare in 2017 – see

However, no one has demonstrated an ability to change the microbiome in a way which improves health. OptiBiotix’s research which we are presenting has changed that. Not only have we demonstrated we can change the microbiome, but we can do this in a very targeted way. More importantly we have demonstrated that by targeting a particular species that has a health benefit (such as our cholesterol reducing strain) we can enhance that benefit. In the case of our own cholesterol reducing strain this lead to a threefold increase in the strains ability to lower cholesterol

Having an ability to alter specific components of a patient’s microbiome is a significant step forward as it creates the potential to precision engineer specific components of the microbiome to prevent, manage and treat disease. This opens up a wide range of opportunities including:-

a. Point i where the RNS identifies how we can enhance current products on the market (specifically probiotic – a market predicted to reach $46.5bn by 2020). This is the basis of our current deal with DSM and CSL who are companies with the foresight to recognise this opportunity. Presenting this data more widely will open up more opportunities

b. Point ii where we are reporting that we have developed capabilities to design ingredients which can modify an individual’s current microbiome to improve health. As the science on the microbiome matures and the association between specific microbial components and disease becomes ever clearer this ability creates opportunities to design ingredients which can enhance the presence of these microbes in the gut (if you like a targeted way of increasing the number of good bacteria over bad bacteria). As these components we have developed are heat resistant and stable during processing this creates the potential for ingredients which could be added to a wide range of food products to reduce weight, control diabetes, and possibly help to reduce cancer risks

There is still work to do in this area and of course we have to prove this works in large scale human studies. However, as reported in our RNS’s we have demonstrated this effect in human gut models which are generally a good indicator. I believe this is a significant breakthrough in microbiome science and as I say in the RNS places OptiBiotix at the forefront of global microbiome research and product development.

I do not believe I have shared any new (and hence market sensitive) information with you in this response. Please feel free to share this more widely.

Best Wishes,

Stephen OHara

Chief Executive

OptiBiotix Health PLC"

[elrico] 24/1/2017 18:40

Cooking the books for someone.

[owenmo] 24/1/2017 17:51

3% retraction, give or take, is par for the course - it being an RNS Tuesday :)

[elrico] 24/1/2017 17:10

Diamond - I would have a word with your tax advisor if I were you. Here is my understanding of it.

Finance Act 2013 and The Individual Savings Account individuals are able to invest in AIM companies through their stocks and shares Individual Savings Accounts (ISAs). ISAs are generally seen as tax efficient as an individual pays no tax on the income
received from ISA savings and investments (including dividends), nor does the individual pay tax on capital gains arising on ISA investments.

[spike_1] 24/1/2017 16:41

But you still pay capital gains tax on an AIM stock if not in an ISA.
Cheers - Mike

[diamond fibre] 24/1/2017 16:35

Thanks Nick .

[nicktopten] 24/1/2017 16:29

you don't pay inheritance tax on aim stocks.... there used to be taper relief on AIM,so if you held without selling for two years or more the tax liability would start to decrease, until five(or 7?) years when it would be nil.